Roche's sub-Q MabThera wins European panel nod; NICE says no to 'societal benefit' test on drugs;

@FiercePharma: Merck KGaA CFO jumps ship amid turnaround he helped engineer; shares slide. Story | Follow @FiercePharma

@TracyStaton: Q4 sales up, 2013 down, esp in US: Bristol-Myers Squibb Reports 4th Quarter and Full Year 2013 Results. Release | Follow @TracyStaton

@EricPFierce: Ranbaxy will need new markets as FDA closes window on U.S., analysts predict. Piece | Follow @EricPFierce

@CarlyHFierce: Bristol-Myers impresses with trimmed-down costs, pumped-up sales. Story | Follow @CarlyHFierce

> Roche's ($RHHBY) subcutaneous formulation of the cancer drug MabThera won a key recommendation for European approval in non-Hodgkin lymphoma. Report

> The U.K.'s cost-effectiveness agency rejected the idea of using a "wider societal benefit" test when evaluating new drugs for use by the National Health Service. Report

> The family of an inmate recently executed in Ohio sued Lake Forest, IL-based Hospira ($HSP), saying the company illegally allowed its drugs to be used for an execution; the company says its distributors have promised not to sell the drugs to prisons. Report

> Hungary's Gedeon Richter said it won European marketing approval for repeated use of Esmya to treat symptoms of uterine fibroids. Report (sub. req.)

> India's Cadila Healthcare decided to pull out of Japan as part of a strategic review of its business. Report

Medical Device News

@FierceMedDev: U.K. researchers unveil an artificial pancreas they've been developing for 20 years. News | Follow @FierceMedDev

@MichaelGFierce: St. Jude places its first Nanostim leadless pacemaker in a U.K. patient. Story | Follow @MichaelGFierce

@EmilyWFierce: Johnson & Johnson's Animas launches new combination insulin pump in Canada. Article | Follow @EmilyWFierce

@GalenMoore: Pfizer misses its endpoint for 2 PhIII trials of dacomitinib in non-small cell lung cancer. Release | Follow @GalenMoore

> 23andMe's genome test raises more questions, this time for ancestry results. Item

> Varian, Toshiba announce a $515M medical imaging deal. More

> Edwards nabs EU nod for next-gen Sapien as competition mounts. News

Biotech News

@FierceBiotech: Is Bristol-Myers fading back in its hot race with Merck for PD-1 lead? More | Follow @FierceBiotech

@JohnCFierce: Scoff warning: This buyout story relates to experimental dendritic cell cancer vaccine tech. Story | Follow @JohnCFierce

@DamianFierce: ICYMI: Big-time pharma contractor Catalent lines up for an IPO worth $100M--or much more. Article | Follow @DamianFierce

@EmilyMFierce: Study: mutations in Russian #TB strain make it drug-resistant. Story via Wired UK | Follow @EmilyMFierce

> Tsunami of biotech IPOs will test investors' appetite for R&D. Article

> A top Pfizer drug flops in two PhIII lung cancer studies. Piece

CRO News

> Report: Indian clinical trials fell 93% last year. Story

> CRO Genae reaches into Germany for device trials. News

> ResearchDx pushes into the Middle East for diagnostics development. Article

> Catalent lines up for an IPO worth $100M--or much more. More

> Covance adding 500 jobs in U.K. nutrition expansion. Piece

> Datatrak, Clinverse team up for clinical trial tech. Item

Biotech IT News

> The clinical trial technology sector could top $5B by 2018, report says. Story

> Sony teams with Illumina to crack the Japanese genome market. More

> Report: Pharma is missing a Big Data opportunity by ignoring social media. News

> The NCI is offering $20M to pilot projects that move cancer genomics into the cloud. Piece

> U.K. to digitize patient health records and sell access to biopharma researchers. Article

> Novo Nordisk taps Trialbee for online recruitment of trial patients. Item

And Finally... A gap in life expectancy between city and country dwellers is widening. Report

Suggested Articles

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.

Weeks after launching a U.S. trial to evaluate IL-6 inhibitor Kevzara for COVID-19, Sanofi and Regeneron have launched a matching study abroad.